Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03630120 | Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | terminated | Phase 2 | 6 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT04955886 | Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 14 | Fujian Cancer HospitalOTHER_GOV | 1 | Jul 9, 2021 | clinicaltrials |
| NCT03463889 | Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer | terminated | Phase 2 | 12 | University of California, San FranciscoOTHER | 1 | Jun 29, 2021 | clinicaltrials |
| NCT03904225 | Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis | unknown | Phase 2 | 220 | Zhejiang Cancer HospitalOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT00031694 | Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2021 | clinicaltrials |
| NCT04917770 | The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 28 | West China HospitalOTHER | 0 | Jun 8, 2021 | clinicaltrials |
| NCT04890522 | An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC | not yet recruiting | Phase 2 / Phase 3 | 622 | Sun Yat-sen UniversityOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT04882462 | Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.(Carpp-1) | unknown | Phase 2 | 100 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | May 12, 2021 | clinicaltrials |
| NCT02762513 | Expansion Trial for Axitinib In Head And Neck Cancer | completed | Phase 2 | 29 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 5, 2021 | clinicaltrials |
| NCT03134846 | Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate(ICON) | unknown | Phase 1 / Phase 2 | 79 | University Medical Center GroningenOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT03390738 | Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy | withdrawn | Phase 2 | 0 | The University of Hong KongOTHER | 0 | May 3, 2021 | clinicaltrials |
| NCT04861467 | Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 155 | Chinese Academy of Medical SciencesOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT04523883 | Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT)(IMPORT) | unknown | Phase 2 | 316 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT03194373 | Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 21 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 12, 2021 | clinicaltrials |
| NCT00896181 | Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 26 | Stanford UniversityOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04826679 | Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC | unknown | Phase 2 | 53 | Sun Yat-sen UniversityOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT03771820 | Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen | unknown | Phase 2 | 136 | NanoCarrier Co., Ltd.INDUSTRY | 8 | Mar 17, 2021 | clinicaltrials |
| NCT02054442 | A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck(COMMENCE) | unknown | Phase 1 / Phase 2 | 52 | Radboud University Medical CenterOTHER | 1 | Mar 12, 2021 | clinicaltrials |
| NCT00084682 | Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2021 | clinicaltrials |
| NCT04769076 | The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma | unknown | Phase 2 | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Feb 25, 2021 | clinicaltrials |
| NCT03072160 | Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2021 | clinicaltrials |
| NCT03668366 | S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma | completed | Phase 2 | 133 | Fudan UniversityOTHER | 1 | Feb 11, 2021 | clinicaltrials |
| NCT02636231 | Endostar for Locally Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 96 | Sun Yat-sen UniversityOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04440917 | Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma(IMplus) | unknown | Phase 2 | 32 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT03908372 | Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 120 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT03915132 | Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 | 47 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT01414426 | Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions | completed | Phase 2 | 20 | University of ChicagoOTHER | 1 | Jan 14, 2021 | clinicaltrials |
| NCT01602315 | A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 179 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 29, 2020 | clinicaltrials |
| NCT00514046 | Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 22, 2020 | clinicaltrials |
| NCT02138214 | Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer | completed | Phase 2 | 117 | University of Wisconsin, MadisonOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT00210470 | A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer | completed | Phase 2 | 27 | Brooklyn ImmunoTherapeutics, LLCINDUSTRY | 0 | Dec 11, 2020 | clinicaltrials |
| NCT01689194 | Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer | completed | Phase 2 | 53 | Seoul National University HospitalOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03655444 | Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy | terminated | Phase 1 / Phase 2 | 6 | Washington University School of MedicineOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT04627961 | A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 33 | National University Hospital, SingaporeOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT01386632 | Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma | completed | Phase 2 | 50 | Sanford HealthOTHER | 1 | Oct 27, 2020 | clinicaltrials |
| NCT04231864 | Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer | withdrawn | Phase 2 | 0 | Alain AlgaziOTHER | 0 | Oct 26, 2020 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04574817 | Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC) | unknown | Phase 2 | 66 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT04553510 | Treatment of Bevacizumab Followed by Steroid in RN | unknown | Phase 2 | 86 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT00603941 | A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel | terminated | Phase 1 / Phase 2 | 19 | Daiichi SankyoINDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT04547088 | Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 27 | Sun Yat-sen UniversityOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT04548271 | Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT00736944 | Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer | completed | Phase 2 | 30 | Washington University School of MedicineOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 7, 2020 | clinicaltrials |
| NCT04220749 | Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma | recruiting | Phase 2 | 68 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Sep 4, 2020 | clinicaltrials |
| NCT04093115 | Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma(HNSCC) | withdrawn | Phase 2 | 0 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 3, 2020 | clinicaltrials |
| NCT04534855 | A Phase II Clinical Study of Treprilimab in the Treatment of Recurrent Nasopharyngeal Carcinoma After Re-irradiation | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 0 | Sep 1, 2020 | clinicaltrials |
| NCT04525066 | Phonosurgical Augmentation After Laser Resection of Early Glottic Carcinoma | completed | Phase 2 | 39 | Ayhman Al AfifOTHER | 0 | Aug 25, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Jul 14, 2021source: clinicaltrials